Disease |
Control
Group [37] |
Test
Group [37] |
||
|
Recommended
Antibiotic Prescribed (No of patients) |
SSI
observed (No of patients) |
Additional
antibiotic in
treatment regime (No of patients) |
SSI
Observed (No
of patients) |
Acute
Gall stone |
Ceftriaxone
/ Ciprofloxacillin [4] |
3 |
Amikacin
& Metrogyl [4] |
Nil |
Cholecystitis |
Ceftriaxone
/ Ciprofloxacillin [16] |
11 |
Amikacin
& Metrogyl [15] |
2 |
Acute
Abdomen |
Ceftriaxone
/ Ciprofloxacillin [4] |
4 |
Amikacin
& Metrogyl [4] |
Nil |
Pancreatitis |
Meropenum
[3] |
3 |
Metrogyl
[4] |
1 |
Appendicitis |
Ceftriaxone/
Cefotaxime [6] |
4 |
Amikacin
& Metrogyl [6] |
1 |
Colonic
Growth |
Ceftriaxone
/ Cefotaxime [4] |
4 |
Amikacin
& Metrogyl [4] |
Nil |
Disease |
Control
Group (14) |
Test
Group (15) |
|||
|
Recommended
Antibiotic Prescribed (No of patients) |
SSI
observed (No of patients) |
Additional
antibiotic in
treatment regime (No of patients) |
SSI
Observed (No
of patients) |
Additional
complications (No of patients) |
Diabetic
Foot [7] |
Augmentin [3] |
1 |
Clarithromycin
[4] |
1 |
G
I upset [3] |
Breast
Abscess [10] |
Amoxycillin
[5] |
1 |
Clarithromycin
[5] |
4 |
Drug
resistant [4] |
Hernia
& Hydrocoele [12] |
Ceftriaxone/
Cefotaxime [6] |
2 |
Amoxycilline
& Clavulonic acid [6] |
2 |
GI
upset [6] |